Nanology Press ReleasesBy Year
2025
2024
2023
2022
2021
2020
2019
2018
2017
NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio
NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor
NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the IASLC North America Conference on Lung Cancer
NanOlogy Announces an Abstract Has Been Accepted for Presentation at the 38th SITC Annual Meeting
Interim Results from a NanOlogy Phase 2 Clinical Trial of its Intratumoral Investigational Drug in the Treatment of Locally Advanced Pancreatic Cancer
NanOlogy Announces Two Abstracts Have Been Accepted for Presentation at AACR Special Conference in Cancer Research: Pancreatic Cancer
NanOlogy Presents Clinical Research at 2023 DDW and ASCO Involving its Large Surface Area Microparticle Investigational Drugs
NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer
NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer
NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site
NanOlogy Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas
NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®
NanOlogy to Present Preclinical Lung Cancer Study Showing Inhaled NanoPac® Resulted in Increased Tumor Regression and Immune Response
NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer
NanOlogy to Present Positive Preclinical Data for NanoDoce® in Treatment of Uro-Oncologic Cancers at 2019 Genitourinary Cancers (ASCO-GU) Symposium
NanOlogy Chief Medical Officer on Panel to Discuss Next Wave of Innovation in IO Therapy at BIO CEO & Investor Conference
Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery
DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
NanOlogy Adds Clinical Trial Sites for Phase 2 Clinical Trials of NanoPac® in Pancreatic Cancer and Pancreatic Mucinous Cysts
NanOlogy to Unveil Positive Preclinical Data for Inhaled NanoPac® in Treatment of Lung Cancer at 2018 ASCO Annual Meeting
NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
NanOlogy to Present Abstract on Preclinical Study of Nebulized NanoPac for Lung Cancer at 2018 ASCO Annual Meeting
NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial for Cutaneous Metastases and DFB Soria Provides an Update on AK Trial
NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference
NanOlogy to Present Update on Cancer Treatment Clinical Program at Biotech Showcase in San Francisco
NanOlogy Announces First Patient Enrolled in a Pancreatic Cancer Phase 2 Clinical Trial of NanoPac® Adding to Trials in Prostate and Ovarian Cancers
NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Mucinous Cysts of the Pancreas
NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
NanOlogy Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Ovarian Cancer
DFB Soria Gives Update on Enrollment in Phase 2 Clinical Trial of SOR007 (Nanoparticle Paclitaxel) Ointment for Actinic Keratosis (AK)
DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
